
Former FDA Commissioner: ‘Cost-Cutting’ May Undo One of Trump’s Best Drug Pricing Achievements
Trump’s FDA cuts disbanded a key generic drug policy team, threatening progress on affordable alternatives to complex medications like Ozempic and inhalers—reversing $26B in consumer savings achieved during his first term.










